T
Tongxin Medical Technology
Designs and manufactures medical devices for use in the healthcare industry
About Tongxin Medical Technology
CH Biomedical, operating in the U.S. as BrioHealth Solutions, Inc., is a medical technology company established in 2008 by Dr. Chen Chen. Dr. Chen has over two decades of experience in the field of ventricular assist devices (VADs), beginning with academic research into the application of magnetic levitation. His journey includes developing the World Heart Levacor VAD before he founded CH Biomedical to create a smaller, more effective artificial heart. The company focuses on developing and commercializing VADs for patients with severe heart failure.
The firm's primary product is a fully magnetically levitated left ventricular assist device (LVAD), known as an "artificial heart." Its first-generation product, the CH-VAD, was launched after seven years of development and is designed to serve as either a bridge-to-transplantation or as destination therapy for individuals with end-stage heart failure. This device, made of titanium alloy, functions as a centrifugal pump that assists a malfunctioning heart by pumping blood from the veins to the arteries. A key feature of the CH-VAD is its fully magnetically levitated flow technology, which suspends the rotor with magnetic forces, allowing for gentler passage of blood cells. The device is notably compact, weighing under 180g, with a thickness of 26mm and a diameter of 50mm, and connects to an external wearable battery via a minimal number of cords. Since its first human implantation in 2017, the CH-VAD received market approval in China in 2021 and has been utilized in over 180 patients across more than 40 hospitals in the country.
Building on the technology of the CH-VAD, the company has developed its next-generation product, the BrioVAD™ Left Ventricular Assist System. This system received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) in May 2024 to begin clinical trials. The BrioVAD aims to enhance portability and overall system performance through several technological innovations while maintaining the blood compatibility of its predecessor. The company, headquartered in Suzhou, China, with a U.S. subsidiary in Burlington, Massachusetts, operates on a business model centered on the development, manufacturing, and sale of these high-end medical devices to hospitals and cardiac centers. CH Biomedical has secured significant funding, including a Series D round of over $100 million, to accelerate its international expansion and continue its product innovation.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 40.6/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Cardiology and cardiovascular, Rumoured $1B, DT and LS, science-based
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jul 2025 | $100M | $400M | HongShan · China Growth Capital · Gaorong Capital · Neovision Capital | ↗ |
| SERIES DOther financing | Jan 2022 | $28M | $110M | Jiantou Huawen Investment · PICC Capital · CICC · HongShan | ↗ |
Growth signals
Latest recorded traffic for Tongxin Medical Technology is 80 monthly website visits, down 98.1% over the last three months. Tongxin Medical Technology's team declined 18.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tongxin Medical Technology in its local ecosystem
The Tongxin Medical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later13 investors entered at this stage
- LGLinden Asset Group
Sequoia
Lake Bleu Capital
Jiantou Huawen Investment
PICC Capital
CICC
HongShan- HCHonghui China
- QCQingchi Capital
- LCLingdao Capital
China Growth Capital
Gaorong Capital- NCNeovision Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tongxin Medical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tongxin Medical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







